若生智能
Drug Database
AL

alternaria allergen SLIT

✓ Approved

HAL Allergy Group · 治疗药物

什么是 alternaria allergen SLIT？

alternaria allergen SLIT 是一种治疗药物，由HAL Allergy Group研发。该药已获批，用于治疗相关适应症，给药途径：Oral (PO)、Sublingual (SL)/Oral Transmucosal。

药物档案

公司HAL Allergy Group
给药途径Oral (PO), Sublingual (SL)/Oral Transmucosal
状态Approved
来源： ClinicalTrials.gov, HAL Allergy Group

治疗适应症

alternaria allergen SLIT 针对 1 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Immune system disordersHypersensitivity✓ Approved

相关研究文献

PubMedScientific reports2026-06-13

Morphological identification of fungi associated with preharvest spoilage of sweet orange (Citrus sinensis L.) fruit in Bilo Nopha, Southwestern Ethiopia.

Adeba Gobena G, Kejela Tekalign T, Atnafu Tesfalem T

Sweet orange (Citrus sinensis L.) is a major fruit crop globally, but fungal pathogens have severely impacted its yield. Bilo Nopha, known for high-quality sweet oranges, has recently faced significant preharvest spoilage. This study aimed to isolate fungal pathogens associated with preharvest spoilage of sweet orange (Citrus sinensis L.) fruit in Bilo Nopha, southwestern Ethiopia. In the present study, a total of 240 symptomatic orange fruit samples were collected from six orchards of study area and fungi pathogens were isolated and characterized to genus level following standard microbiological techniques. A total of 430 fungal isolates were recovered. Pseudocercospora spp. were most prevalent (45.0%), followed by Colletotrichum spp. (42.1%). Alternaria spp. showed moderate prevalence (30.4%) with significant site variation (15.0-37.5%, P < 0.05). Rhizopus spp. were consistent across sites (20-30%, total 27.1%), while Fusarium and Phytophthora spp. had the lowest rates (17.5% each). Pseudocercospora spp., Colletotrichum spp., and Phytophthora spp. were identified as the primary fungal pathogens, whereas Alternaria spp., Rhizopus spp., and Fusarium spp. were involved as secondary or opportunistic pathogens. Species-level identification and targeted management are recommended to reduce losses and sustain production.

PMID 42286037
阅读全文 →
PubMedPlant biotechnology journal2026-06-13

ERF Transcription Factor NaERFIDOG Regulates JA-Induced Defence and Growth Inhibition in Nicotiana attenuata Upon Alternaria alternata Infection.

Zhao Luyan L, Song Na N, Wang Lei L, Wu Jinsong J

Jasmonate (JA) regulates defence responses in plants. However, JA-induced defence often results in growth inhibition. This process is largely mediated by MYC2, the master regulator of JA signalling. Nevertheless, the underlying molecular mechanisms have not yet been fully uncovered. Here, we discovered that the ERF transcription factor NaERFIDOG plays a key role in the JA-induced defence over growth in Nicotiana attenuata upon infection by the notorious fungal pathogen Alternaria alternata. NaERFIDOG expression was directly controlled by JA through NaMYC2a/b. Plants silenced or knocked out for either NaERFIDOG or both NaMYC2a and NaMYC2b exhibited similar phenotypes: they were both more vulnerable to A. alternata but grew larger. However, stable overexpression of NaERFIDOG increased resistance to the fungus and reduced growth in both wild-type (WT) plants and those co-silenced with NaMYC2a/b to a similar extent. Further analysis indicated that NaERFIDOG binds directly to the promoters of the biosynthetic genes for scopoletin, JA and GA, including NaF6'H1, NaAOS and NaKAO1-like, thereby activating scopoletin and JA biosynthesis while suppressing GA biosynthesis. Finally, our results revealed that both increasing scopoletin levels and reducing GA biosynthesis were involved in JA-induced disease resistance and growth inhibition. Thus, our study revealed how JA prioritizes defence against A. alternata over growth by a novel regulatory network, JA-MYC2-ERFIDOG-Scopoletin/JA/GA. These findings provide new insights into the molecular mechanisms underlying the trade-off between defence and growth in plants and highlight the key role of NaERFIDOG in the biosynthesis of scopoletin, JA and GA.

PMID 42287000
阅读全文 →
PubMedAllergy2026-06-13

Cashew Reaction Thresholds, Its Predictors, and Very Low Validated Safe Doses, in a Large Allergic Population (Nut CRACKER Study).

Nachshon Liat L, Blom W Marty WM, Bijlsma Sabina S, Goldberg Michael R MR et al.

Cashew is a widespread food allergen with a high rate of severe, and near-fatal reactions. Understanding cashew reaction thresholds and its predictors might improve patients' management and precautionary allergen labeling. A prospective cohort study with post hoc analysis of cashew oral food challenges (OFCs) performed at Shamir (Assaf-Harofeh) Medical Center between July-2014 and May-2023. OFCs were performed according to either a diagnostic protocol in patients with suspected cashew allergy or an oral immunotherapy (OIT) protocol, intended to identify individual single highest tolerated dose (SHTD) at the beginning of OIT. No observed adverse effect levels and lowest observed adverse effect levels (NOAEL and LOAEL, respectively) of each OFC were identified. OFCs with extended dosing intervals were performed to determine individual validated SHTD (safe dose). Overall, 293 positive cashew OFCs (155 diagnostic-OFCs and 138 OIT-OFCs) were analyzed. The ED01 and ED05 for all patients were 0.2 mg (range 0.1-4.1) and 0.9 mg (range 0.2-14.8) for discrete, and 0.2 mg (range 0.1-11.7) and 1.2 mg (range 0.3-47.1) for cumulative doses, respectively. Pistachio co-allergy (p < 0.0001), higher sIgE to cashew (p = 0.004), Ana-o-3 (p < 0.001) and pistachio (p = 0.02), and an OIT-OFC protocol (p < 0.001) were associated with lower cashew thresholds. Cashew safe doses for 90% and 75% of the population were only 0.1 and 1 mg protein, respectively compared to 1 and 7.5-10 mg protein for sesame, walnut and peanut. The population cashew ED05 is within the range of other nuts and seeds, but safe doses are lower. Pistachio co-allergy and higher cashew and pistachio sensitization are risk factors for low reaction thresholds.

PMID 42285894
阅读全文 →
PubMedCurrent opinion in allergy and clinical immunology2026-06-13

Probiotics in allergic disease: from adjunct supplement to immune-modifying strategy (2026 update).

Raho Giorgio S GS

Allergic diseases continue to increase globally, and accumulating evidence implicates early-life microbial exposures as central determinants of immune tolerance. This review synthesizes advances from 2024 to 2026 regarding probiotic-mediated immune modulation and their translational implications in allergy prevention and therapy. Recent studies confirm strain-specific expansion of Foxp3+ regulatory T cells, suppression of Th2 polarization, reinforcement of epithelial barrier integrity, and durable epigenetic stabilization mediated by short-chain fatty acids such as butyrate. Clinical trials demonstrate benefit in perinatal prevention of atopic dermatitis, modulation of allergic rhinitis symptoms, early-life asthma risk reduction, and probiotic-adjuvanted oral immunotherapy. Probiotics are evolving from adjunctive supplements to biologically active immune modulators with disease-modifying potential. Integration with allergen immunotherapy and precision microbiome profiling may redefine preventive and therapeutic strategies in allergic disease.

PMID 42286957
阅读全文 →
PubMedExperimental eye research2026-06-13

Resolvin E1 ameliorates obstructive meibomian gland dysfuction in oleic acid induced mice model.

Wang Han H, Yang Xiaowei X, Zeng Meizhen M, Ouyang Bo-Wen BW et al.

This study explores the effects of Resolvin E1 (RvE1), a natural agonist of peroxisome proliferator-activated receptor-γ (PPAR-γ), in a novel mouse model of obstructive Meibomian gland dysfunction (oMGD) induced by oleic acid. Oleic acid was applied at varying concentrations to the eyelid margin to identify the optimal dose for MGD induction. Morphological and pathological changes in Meibomian glands (MGs) were assessed using slit-lamp examination, histological staining (H&E, Oil Red O), and molecular analyses. Male BALB/c mice (6-8 weeks) were randomly assigned to RvE1 treatment or PBS control groups, receiving eye drops twice daily for four weeks. Parameters such as tear secretion, tear breakup time (BUT), fluorescein staining, inflammatory cytokines, and PPAR-γ expression were evaluated. Oleic acid treatment at 100% concentration caused significant MG obstruction and atrophy after eight weeks, establishing an oMGD model. The severity of obstruction correlated with oleic acid concentration. RvE1 treatment upregulated PPAR-γ expression, reduced inflammatory cytokines, alleviated MG obstruction and atrophy, and improved tear film stability. This oMGD model mimics human oMGD, offering a reliable tool for studying MGD pathophysiology and therapeutic strategies. RvE1 shows promise as a potential therapeutic for oMGD by reducing inflammation and enhancing MG secretion.

PMID 42285403
阅读全文 →
PubMedClinical and translational allergy2026-06-13

Temporal Patterns of Allergen Sensitisation in the General Population: The LEAD Study.

Lim Charmaine J M CJM, Omar Abdelrahman A, Pötscher Severin S, Breyer Marie-Kathrin MK et al.

Allergic sensitisation is traditionally viewed as a stable trait despite studies suggesting that it may vary across life-course. This study aims to provide longitudinal evidence of allergic sensitisation and its associated factors in the general population. Aeroallergen sensitisation was assessed in the Austrian population-based cohort using repeated skin prick testing (SPT) across 3 visits (mean visit interval, 4.25 ± 0.33 years). Longitudinal sensitisation patterns were characterised as stable nonsensitised, stable sensitised, new-onset, resolution or fluctuating. We examined demographic, metabolic, behavioural, environmental and immunological factors across age strata (< 18, 18 ≤ 40, 40 ≤ and ≥ 60 years). Among 5046 individuals with follow-up and valid SPT in all 3 visits, 54.4% remained stably nonsensitised and 30.6% stably sensitised, 5.6% experienced resolution, 4.8% new onset and 4.6% fluctuating sensitisation. New onset expectedly predominated in < 18 years, fluctuation in 18 ≤ 60 years and resolution in ≥ 60 years, indicating that sensitisation is modifiable and time-varying. Stable sensitisation was strongly associated with parental allergy and blood eosinophils while cumulative smoking modestly reduced its likelihood. Fluctuation was linked to adiposity (in adults ≥ 40 years old) and environmental exposures. Aeroallergen-specific analysis showed new-onset sensitisation was driven by outdoor allergens (ragweed, tree pollens and pets) whereas fluctuation was driven by seasonal pollens. Although predominantly stable, allergic sensitisation is dynamic and exhibits substantial temporal variation. Resolution and fluctuation occur across all ages and new sensitisation can emerge well into adulthood. These findings challenge the traditional view of fixed sensitisation and suggest it reflects a modifiable phenotype shaped by age and environmental and lifestyle exposures.

PMID 42286327
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多alternaria allergen SLIT